In utero cell and gene therapies constitute alternative strategies to the postnatal treatment of inherited diseases. Fetal hematopoietic progenitors could be a potential source of donor cells for these strategies. In this study, hematopoietic lineage-negative fetal liver cells from 14.5-day-old fetuses were transduced under different cytokine and culture combinations using a lentiviral vector expressing the enhanced green fluorescent protein (EGFP). When cells were transduced for 6 h in the presence of mSCF, hTPO and FLT3-L in retronectin-coated dishes at a multiplicity of infection of 10 transduction units/cell, up to 70% of granulo-macrophage colony-forming cells expressed the EGFP reporter gene. In utero transplantation experiments revealed that conditions leading to high transduction efficiencies were associated with poor engraftments of syngeneic recipients. Significantly, this effect was associated with the detection of a humoral and cellular immunoresponse against the transgenic protein. Moreover, the humoral response against EGFP was detected not only in in utero transplanted recipients but also in the operated mothers, suggesting the maternal origin of the anti-EGFP immunoresponse. These observations reinforce the necessity of carefully studying the potential immunoresponses in future prenatal gene therapy protocols.
INTRODUCTION
Hematopoietic transplantation is the therapy of choice for a wide range of blood disorders in adults. 1 However, for the successful engraftment of exogenous healthy cells, this type of transplant requires a compatible donor and myelosuppressive treatment, and major complications may arise, such as graft-versus-host disease and graft rejection, compromising both the success of the treatment and patient survival. 2 Further, in some inherited diseases, hematopoietic transplantation after birth or in adulthood is not always effective because the disease may have already had an effect during fetal development. 3, 4 Advances in genetic testing and the possibility of sampling chorionic villus cells during the first trimester of gestation facilitate early prenatal diagnosis. 5 These technical improvements permit the treatment of a fetus during a theoretical window of opportunity from the last weeks of the first trimester to the second trimester in humans, in which the early gestational immune system is undergoing a process of self-education. Thus, in utero hematopoietic cell transplantation (IUHCT) could provide the appropriate conditions for specific tolerance to allogeneic cells or to genetically corrected autologous cells. 6, 7 In effect, in utero transplantation of hematopoietic stem cells (HSCs) has been used to treat inherited diseases over the past 30 years. First attempts were performed in mice and sheep, and significant levels of chimerism achieved without myeloablative treatment. In utero transplantation in human fetuses has been successful only in immunodeficient patients. 8 Evidence of in utero engraftment of allogeneic cells has been reported in different animal models and in humans. 9 However, the recently described failure of long-term chimerism after IUHCT of allogeneic grafts in mouse models 10 suggests the immunocompetent status of the fetus. Thus, the use of autologous, genetically corrected cells for transplant could avoid potential problems associated with the rejection of allogeneic cells by the recipient. In a previous study, we reported the long-term, multilineage engraftment of retrovirally transduced adult bone marrow (BM) HSC after IUHCT of syngeneic mouse fetuses. 7 These models of ex vivo gene therapy avoid vector infusion in the animals, thus limiting the transduction of non-target cells (that is, germline) and reducing the risk of immunoreaction with the transgene. 4, 11 Although the principal sources of hematopoietic cells for transplantation in humans are adult BM, mobilized peripheral blood and umbilical cord blood, fetal liver (FL) hematopoietic progenitors are a good alternative for IUHCT because both recipient and graft coincide in developmental stage. 8 In addition, the expression profiles of adhesion molecules in FL-HSCs (FL-HSCs) 12 could confer cells improved homing and engraftment capacities over adult HSCs in response to IUHCT. In a gene therapy context, recent studies have shown that FL-HSCs proliferate more actively than adult BM HSCs 13, 14 and are differentially regulated by transcription factors. 15 These findings suggest that specific experimental conditions may be required for the transduction of FL-HSCs with integrative vectors. Some success has already been described for the transplant of genetically corrected FL-HSCs in newborn mice. 16 However, as far as we are aware, the possibility of engrafting mice after the in utero transplant of FL-HSCs transduced with integrative vectors has not yet been reported.
In this study, we optimized the conditions required to transduce FL hematopoietic progenitors using lentiviral vectors (LVs) and examined the long-term engraftment capacity of these lentivirally transduced FL-HSCs following IUHCT. Our findings unveil the existence of humoral and cellular immunoresponses against the transgenic protein after in utero transplantation.
RESULTS
Efficient lentiviral transduction of hematopoietic FL progenitors in the presence of SCF, hTPO, FLT3-L and retronectin To improve the lentiviral transduction of FL-HSCs, 5Â10 5 lineagenegative (Lin À ) FL cells from 14.5-day-old mouse fetuses (immunophenotyping of this population is showed in Supplementary Figure S1 ) were transduced for different times at multiplicities of infection (MOI) of 5 and 10 TUs per cell, and different combinations of growth factors (mSCF+hIL-11 versus mSCF+hTPO+FLT3-L), both in the presence and the absence of retronectin. After transduction, cells were washed and cultured in semisolid media to analyze the contents and transduction efficiencies of committed progenitors (Figure 1 ). To minimize cell manipulation and bearing in mind that FL progenitors are actively proliferating, cells were not prestimulated but were transduced for very short incubation periods. As shown in Figure 1a , highest transduction levels (up to 70% of CFU-GM positive for enhanced green fluorescent protein (EGFP)) were recorded after 6 h of transduction (MOI 5 or 10) using mSCF+hTPO+FLT3-L in the presence of retronectin. The comparison of the number of colonies generated from mock-transduced samples and samples transduced with the LVs indicates that the LV transduction did not affect the viability of the progenitors present in the samples (Figure 1b) . Transduction periods longer than 6 h affected the viability of FL progenitors (data not shown). Incubating the Lin À FL cells in the presence of retronectin increased both the percentage of transduced CFU-GM and the total number of colonies, regardless of the culture conditions used (Figure 1b) . Figure 2 and Supplementary Figure S2) . No specific mortality was observed in any of the transplant groups (not shown), indicating sufficient numbers of progenitors/ HSCs were transplanted after the transduction protocol, in good consistency with data obtained in the clonogenic studies of Figure 1b . A significant proportion of these cells (up to 45%) expressed the EGFP transgene ( Figure 2c) . As for the CFU-GMs, the group transplanted with cells that had been transduced in the presence of mSCF, FLT3-L, hTPO and retronectin showed the highest levels of EGFP-positive peripheral blood cells (Figure 2c ). An average of 30% EGFP-expressing cells was achieved 90 days after transplant. BM analyses performed at 180 days after transplant, before secondary transplants (see below), suggested the stability of the transgene expression in the long term (Figure 3) .
To confirm the long-term engraftment of transduced FL-HSCs, 5Â10 6 BM cells from primary recipients were transplanted into secondary myeloablated recipients (Figure 3) . Two animals per group were selected as donors for the secondary transplant. In all the experimental groups, secondary recipients were completely engrafted with FL-HSC-derived cells and the percentage of engraftment was maintained up until 60 days after transplantation (Figure 3a) . Moreover, these mice showed similar or even higher percentages of EGFP-expressing cells in peripheral blood compared with primary recipients (Figure 3b 
Engraftment of lentivirally transduced Lin À FL cells in fetal mice
In utero transplantation experiments were performed as two different experimental groups. The first group of fetuses was transplanted with FL progenitors transduced in the presence of mSCF and hIL-11, which conferred moderate transduction efficiencies. The second group was transplanted with FL progenitors transduced in the presence of mSCF, FLT3-L and hTPO in retronectin pretreated plates, which allowed a higher transduction efficacy of FL progenitors and HSCs. In both groups, cells were infected for 6 h at a MOI of 10 TUs per cell. As control, an in utero transplantation (IUT) with non-manipulated cells was also performed (Supplementary Table S1 ).
To check for the presence of donor cells in the in utero transplant recipients, donor engraftment levels were determined up until one year after transplant. Representative dot-plot analyses are shown in Figure 4a . Results obtained at 30, 60 and 90 days after birth are represented in Figures 4b and c. When the IL-11/SCF combination was used for transduction, 68% of the animals born showed detectable (40.1%) stable engraftment of donor cells. Chimerism levels in this group were similar to those observed in mice in utero transplanted with non-manipulated cells. However, the percentage of engrafted mice was significantly lower (35%) when the FL3/TPO/SCF/RN combination was used (see Supplementary Table S1 ). Also, in this second group, donor engraftment rates were significantly lower (around 0.2 versus 2% in the former group; Figure 4b we examined the presence of anti-EGFP antibodies in the serum of recipients transplanted with cells transduced in the presence of mSCF+FLT3-L+hTPO (data obtained at 5 months after birth). A total of 31 out of 51 animals showed specific antibody responses against the exogenous protein. None of the mice showing anti-EGFP antibodies presented EGFP-expressing cells, despite the fact that 26% of these animals had been long-term engrafted with exogenous FL cells. According to chimerism and the presence of anti-EGFP antibodies, we were able to establish four different groups of recipients ( Figure 5 ): mice engrafted with exogenous cells without anti-EGFP antibodies and with EGFP-expressing cells (region G4); mice engrafted with exogenous cells with anti-EGFP antibodies and without EGFP-expressing cells (region G1); and non-engrafted mice that were positive (region G2) or negative (region G3) for anti-EGFP antibodies. Remarkably, animals with EGFP + cells (4 out of 51 with 6-60% of EGFP + long-term engrafted cells) were only observed in the group that showed no antibodies against the transgenic protein ( Figure 5 ).
To examine the type of specific humoral immunoresponse produced in these animals, nine mice were injected with 2 mg of recombinant EGFP at 5 months after birth. Serum was collected every 2 days after the injection and immunoglobulins G (IgGs) and immunoglobulins M (IgMs) against EGFP determined by enzymelinked immunosorbent assay (Figures 6a and b, respectively) . Significantly, animals that showed a secondary response to EGFP were always negative for EGFP + cells.
Cell responses to EGFP were assessed in 12 in utero transplanted mice by inducing EGFP-specific proliferation and INFg release by activated cells. Non-engrafted animals as well as animals engrafted with EGFP À exogenous cells showed cell responses against EGFP (Figures 6c and d) . Collectively, these data point to a complete immunoresponse elicited by the EGFP that impairs engraftment and eliminates EGFP-expressing cells.
Transgene silencing in lentivirally transduced and in utero transplanted FL cells To determine whether, besides the specific immunoresponse, transgene silencing was taking place in animals transplanted in utero with transduced cells, the presence of EGFP-LV proviruses in animals showing exogenous engraftment was analyzed by PCR in peripheral blood cells 1 year after birth. All the animals analyzed, scoring either positive or negative for EGFP expression, showed the presence of the EGFP provirus, indicating silencing of the EGFP transgene after in utero transplantation. Interestingly, we noted that mice with EGFP + cells presented a viral copy number that was inversely proportional to the percentage of EGFP + cells (Figures 7a and b) .
The maternal immunological response against the transgene impairs the hematopoietic chimerism in recipient mice after in utero transplantation of lentivirally transduced cells To investigate whether any leakage of donor cells and/or reabsorption of donor cells within aborted fetuses could induce an immunoresponse of the injected mothers against the transgene, serum samples extracted from the mothers at 2 days after surgery and at 2 days postpartum were analyzed for the presence of anti-EGFP antibodies. Additionally, serum samples from the pups at 2 days after transplant (17.5-day-old fetuses) and at 2 days after birth were also analyzed. We investigated a primary immunoreaction by means of IgM production. As shown in Figure 7c , although no IgM anti-EGFP antibodies were observed in the pups, significant levels of anti-EGFP IgM antibodies were recorded in dams undergoing the intrauterine administration of EGFP + LV-transduced cells. No significant levels of anti-EGFP IgG antibodies were detected at this time because of the very short time period between antigen exposure and serum IgG evaluation (data not shown). To further check maternal transfer of anti-EGFP immunoresponse, in utero transplanted pups with lentivirally transduced cells were transferred to foster mothers upon delivery. In no instance, significant IgG antibodies were detected in pups raised with foster mothers, whereas in two out of five pups raised with operated mothers, anti-EGFP IgG antibodies were detected at 4 weeks after birth (Supplementary Figure S3) .
DISCUSSION
This study was designed to test the engraftment capacity of genetically marked FL hematopoietic progenitors after their transplantation into syngeneic 14.5-day-old fetuses. As FL cells show different characteristics to adult BM cells, both in terms of their viral transduction and hematopoietic repopulation properties, 17 we explored specific ex vivo manipulation protocols capable of transducing FL progenitor cells. The highly proliferative stage of FL-HSCs 13 allowed us to shorten the lentiviral transduction procedure, minimizing the manipulation steps (that is, prestimulation time) that could compromise the repopulation capacity of FL-HSCs. The percentages of EGFP + progenitors obtained after transduction protocols of 3 h were not significantly affected by the transduction conditions used in our experiments. Transductions of 6 h were more reproducible and efficient, and revealed a benefit of using retronectin-pretreated plates while manipulating the samples. When compared with mock-transduced cells, the transduction did not affect the colony-forming ability of FL progenitors. We used VSV-Gpseudotyped LVs, which do not attach to the CH-296 fragment of fibronectin (retronectin). 18 However, our results are consistent with previous observations showing that retronectin improves in vitro cell survival and gene transfer, independently of viral tropism. 19 Several groups including ours have described that the combination of hIL-11 and mSCF maintains the BM HSC compartment in culture 20, 21 and facilitates the transduction of adult hematopoietic cells using viral vectors. However, we did not observe similar effects herein using FL cells, and low transduction percentages were obtained when this combination of growth factors was used. These data are consistent with those of Bowie et al. who observed an inhibitory effect of hIL-11 on the self-renewal capacity of FL-HSCs cells. 22 In contrast, we obtained EGFP + progenitor proportions in excess of 59%, while preserving the total number of CFU-GMs, using the combination mSCF, FLT3-L plus hTPO during the transduction period. This combination of factors has been widely used for culture maintenance and transduction of umbilical cord blood hematopoietic progenitors. 23, 24 However, as far as we know, this is the first report of the efficacy of this combination of cytokines when used for the transduction of mouse FL hematopoietic progenitors.
Our in vivo assays revealed the repopulating capacity of transduced FL cells after transplantation into irradiated adult mice, irrespective of the combination of cytokines used during the transduction procedure ( Figure 2 and Supplementary Figure S2) . However, the percentage of transduced cells recorded in recipient animals was always higher when the mSCF, FLT3-L and hTPO combination was used. Additionally, the percentage of EGFP + cells was kept stable until 90 days after transplant in primary recipients and for 60 days after transplant in secondary recipients (the last observation period). Altogether, our data indicate that FL repopulating hematopoietic cells can be efficiently transduced utilizing LVs at low MOI and short periods of exposure to the vector using a defined combination of cytokines (mSCF, FLT3-L and hTPO) and in the presence of retronectin.
In our IUT experiments, we observed higher chimerism levels, similar to those obtained with non-manipulated cells (see Supplementary Table S1 ), when mSCF and hIL-11 were used during transduction than when mSCF+FLT3-L+hTPO were used ( Figure 4 and Supplementary Table S1 ). However, significant percentages of EGFP + cells were not observed by flow cytometry in recipient mice when the first combination of growth factors was used. On the other hand, the percentage of engrafted mice was lower when transplanted cells were transduced in the presence of mSCF, FLT3-L and hTPO. Under these latter conditions, we were able to detect higher proportions of EGFP + cells in the engrafted animals. These lower percentages of engrafted mice are therefore the outcome of the conditions that mediated high transduction efficiencies in the grafts (mSCF, FLT3-L, hTPO and retronectin; 6 h; MOI 10) and suggest a mechanism of cell rejection in these animals. Similar data have been recorded after the in utero transplantation of allogeneic BM cells 25 or transduced syngeneic adult BM. 7 In our humoral immunoresponse assays, 61% of transplanted mice exhibited antibodies against EGFP in serum. Cell immunoresponses were also observed. Interestingly, whereas animals showing an EGFP immunoresponse did not present EGFP + cells and displayed a low exogenous engraftment capacity, mice without an anti-EGFP immunoresponse were more efficiently engrafted with transduced EGFP-expressing cells. These data indicate that engraftment failure and the loss of EGFP + cells in in utero transplant recipients are due, at least in part, to an immunoresponse against cells expressing the exogenous transgenic protein.
One of the proposed advantages of in utero cell and gene therapy is the preimmune status of the fetus, yet there are a number of indirect arguments supporting an immunologic barrier against engraftment.
The fact that only immunodeficient human fetuses have obtained a clear clinical beneficial effect from IUHCT illustrates this engraftment barrier. 2, 8 Moreover, T cells showing TCR rearrangement have been observed in human FL in the 13th week of gestation, 26 and FL NK cells and fetal T cells have been demonstrated alloreactive in vitro. [27] [28] [29] These lines of evidence could indicate the engraftment failure of FL hematopoietic cells transplanted in utero in allogeneic recipients. 30, 31 Recent studies suggest that an immunoreaction takes place when the fetus is exposed to allogeneic cells. 10 Interestingly, this reaction has been described as caused, at least partially, by alloantibodies present in maternal milk. 32 Effectively, we detected anti-EGFP antibodies in operated mothers as early as 2 days after intrauterine transplantation, suggesting that these antibodies could be present in the maternal milk later on, thus mediating similar immunoresponses as those described for alloantibodies. 32 Moreover, if in utero transplanted pups are transferred to non-operated foster mothers upon delivery, no immunoresponse against EGFP is observed. Our observations therefore indicate that immunoresponses, including T-cell reactivity, against foreign transgenic proteins can be generated in an in utero transplantation setting and this immunoresponse has a maternal origin.
Tolerance to EGFP and other exogenous proteins has been widely described in irradiated adult mice. [33] [34] [35] [36] [37] Additionally, in numerous studies, in utero transplanted mice have revealed the long-term engraftment of transduced cells expressing transgenes. 7, 11, 36, [38] [39] [40] Tolerance to allogeneic cells has also been described in prenatal transplants, and this has been used to induce complete chimerism after a postnatal boost. [41] [42] [43] In our experiments, a number of in utero transplanted mice developed tolerance to EGFP after transplantation and maintained the long-term engraftment of EGFP + cells (see G4 group in Figure 5 ), indicating that this phenomenon can eventually take place after in utero transplantation. Interestingly, animals showing EGFP + cells in the long term exhibited low proviral copy numbers per cell, suggesting that low expression of the foreign protein could facilitate immune tolerance after surgery for IUT. Thus, in the IUHCT setting, the transplant of limited numbers of transduced cells and the use of weak promoters 44 could limit the immunoresponse raised against the foreign transgene.
In summary, FL hematopoietic progenitors may prove to be a good source of cells for genetic correction and subsequent in utero transplantation to treat inherited diseases at very early stages. However, our findings indicate that special precaution should be taken to avoid potential maternal immunoresponses that could limit the efficacy of this therapeutic strategy.
MATERIALS AND METHODS Mice
For adult or in utero hematopoietic transplants, F1 hybrids of strains B6.SJLPtprcaPep3b/BoyJ and DBA/2J (CD45.1/CD45.2 phenotype) were used as donors, and F1 hybrids of strains C57BL/6J and DBA/2J (CD45.2/CD45.2 phenotype) as recipients. Mice were kept under high-standard conditions (HEPA-filtered air, regulated temperature of 22 1C, light/dark cycle of 12 h and allowed food and UV-irradiated water ad libitum) and routinely screened for pathogens. All experimental procedures were carried out according to the 
Lentivirus supernatants
Cells (HEK-293T) were transiently transfected with three plasmids codifying the envelope and packaging viral sequences, pMD2.VSV.G, pMDLg-pRRE and pRSV-REV, and a transfer plasmid codifying the EGFP reporter gene under the control of the cytomegalovirus promoter, pRRLsin18.PPT.CMV.EGFP.Wpre (kindly provided by Dr Naldini). Cells (293 T) were plated on 150 cm-diameter plates; transfection was conducted when confluence was about 80% as previously described. 45, 46 The supernatant was collected 30 h after transfection and centrifuged to concentrate the viral particles. Virus pellets were resuspended in phosphate buffered saline (PBS) and frozen at -80 1C until use. Functional titers of infective LVs were determined in HT1080 cells, plated at 3.5Â10 4 cells per well in 24-well plates and infected overnight with different dilutions of LV supernatants. Cells were washed and incubated with fresh medium, and proportions of EGFP + cells were determined 5 days later by flow cytometry, as described. Titers between 10 8 and 10 9 TU ml À1 were routinely obtained.
Donor FL progenitors
FL cells were obtained from 14.5-day-old fetuses. FLs were disaggregated and filtered to remove cell fragments and clusters. The cells were resuspended in PBS 1X+0.5% bovine serum albumin+2mM EDTA (PBE) and subjected to HSC enrichment by lineage depletion. Lin À cells were sorted using the mouse Lineage Cell Depletion Kit (Miltenyi Biotech, Bergisch Gladbach, Germany) following the manufacturer's recommendations. Briefly, cells were stained with a biotinylated lineage antibody cocktail (including the lineage antigens CD5, CD45R (B220), CD11b, Gr-1 (Ly-6G/C), 7-4, and Ter-119) for 10 min at 4 1C. Next, the cells were stained again with anti-biotin MicroBeads (Miltenyi Biotech) for 15 min at 4 1C and then washed with PBE and subjected to negative immunomagnetic selection on an MS-type column (Miltenyi Biotech). Lin À cells were washed with PBE and resuspended in PBS. On average, a 90%-pure population of Lin À was obtained, the recovery being 30-60% of the input number of Lin À cells.
Transduction of Lin À cells using LVs
Lin À cells were resuspended in Iscove's Modified Dulbecco's Medium (Biowhittacker, Walkersville, MD, USA) supplemented with 20 fetal bovine serum, 1% glutamine and 0.5% penicillin-streptomycin at a density of 5Â10 5 cells/ml. Viruses were added at different MOI for different times of infection. During transduction, the medium was supplemented with one of two different combinations of cytokines: hIL-11 and mSCF (100 ng/ml each, provided by R&D Systems, Minneapolis, MN, USA), or mSCF (100 ng/ml; R&D Systems), FLT3-L (100 ng/ml; Miltenyi Biotech) and hTPO (300 ng/ml each; R&D Systems), in the absence or presence of retronectin (Takara Shuzo, Otsu, Japan). After this period of time, cells were washed to remove the viruses and resuspended in Iscove's Modified Dulbecco's Medium.
In vitro colony forming unit assays
To count myeloid colony-forming units (CFU-GM), FL cells were seeded in MethoCult GF M3534 culture medium (StemCell Technologies, Vancouver, BC, Canada), plated in triplicate on 35-mm plastic tissue culture plates (Nunc, Roskilde, Denmark) and cultured at 37 1C in 5% CO 2 and fully humidified air. After 7 days of plating, colony numbers and EGFP + colonies were scored.
Hematopoietic transplant in adult recipients
In all, 8-to 12-week-old recipients were irradiated following a myeloablation regimen (11 Gy split into two doses, 24 h apart) using a Philips MG324 X-ray device (Philips, Hamburg, Germany) set at 300 kV, 10 mA, to deliver a dose rate of 1.03. Gy/min. In all, 2 to 3Â10 5 Lin À viable-transduced cells from syngeneic 14.5-day-old FLs were transplanted into five adult recipients per group. At 30, 60 and 90 days after transplantation, peripheral blood from these animals was obtained and analyzed for chimerism by flow cytometry. For secondary transplants, 5Â10 6 BM cells were injected per secondary recipient.
IUHCT
On day 14.5 after mating, pregnant females were anesthetized by inhaled isoflurane anesthesia (Sigma-Aldrich, St Louis, MO, USA). The abdomen was accessed by a midline laparotomy and the uterine horns exposed. Each fetus was injected intraperitoneally with 2 to 3Â10 5 viable Lin À cells in 5 ml of PBS using a 100 mm beveled glass micropipette. Fetuses were rehydrated with PBS and reintroduced into the peritoneal cavity, which was closed in two planes using reabsorbable suture (Ethicon PDS II 5/0; Johnson & Johnson, Brussels, Belgium). As analgesia, each mother was then injected subcutaneously with 0.15 mg kg À1 body weight of buprenorphine (Buprex, Reckitt Benckiser Healthcare Ltd., Nottingham, UK).
Chimerism
Chimerism was assessed in peripheral blood samples from adult and in utero transplanted mice (primary recipients), and from secondary recipients. Blood was taken after a small tail vein incision, and chimerism was assessed by flow cytometry, using an anti-CD45.1-PE antibody (BD Pharmigen, Palo Alto, CA, USA). A minimum number of 10 4 -10 5 viable cells was acquired. Off-line analysis was performed using CXP software (Beckman Coulter, Hialeah, FL, USA). The presence of transgene-expressing cells was determined through their EGFP expression.
Detection of anti-EGFP antibodies
Mouse sera were collected and stored at -20 1C until the end of the experiment. Recombinant EGFP protein (Biovision Research Products, CA, USA) was diluted to 3 mg/ml in carbonate-bicarbonate buffer (Sigma-Aldrich) and adsorbed to enzyme-linked immunosorbent assay plates overnight (Maxisorp F96, Nunc Thermo Fisher Scientific, Roskilde, Denmark). The plates were blocked with 5% bovine serum albumin in PBS for 1 h at 4 1C. Mouse sera were diluted in PBS with 5% bovine serum albumin and added to the plates after blocking, followed by incubation for 1 h at room temperature. The plates were washed with 0.05% Tween in PBS. Bound antibodies were detected using goat anti-mouse IgM or IgG horseradish peroxidase (Sigma-Aldrich). Antibodyantigen complexes were visualized using 3,3¢,5,5¢-tetramethyl benzidine substrate (Pierce Biotechnology, Rockford, IL, USA). The reaction was stopped using 0.18 M H 2 SO 4 . Absorbance was read at 450 nm using a Tecan Genius Pro microplate reader (Tecan Trading AG, Männedorf, Switzerland). The positive signal was at least double the background absorbance. A pool of sera from wildtype mice was used as the negative control.
Analysis of EGFP-specific T-cell proliferation
Splenocytes were isolated from mouse spleen and dispersed in 10 ml of Dulbecco's modified Eagle's medium (Gibco, Grand Island, NY, USA). Erythrocytes were lysed with NH4Cl 0.84% and washed three times in Dulbecco's modified Eagle's medium (Gibco). Cell counts and viability were determined by trypan blue exclusion. A total of 2Â10 5 splenocytes were incubated with 10 mg/ml recombinant EGFP at 37 1C in a humidified 5% CO2 atmosphere. On day 3, 10 U recombinant IL-2 (R&D Systems) were added. After 7 days of incubation, the cells were pulsed for the last 18 h with [3 H] 1 thymidine (1 mCi per well, Moravek Biochemicals, Brea, CA, USA). Finally, cells were harvested (Tomtec, Orange, CT, USA), and [ 3 H] 1 thymidine incorporation was measured using a b-liquid scintillation counter LKB 1205 Betaplate (Wallac, Perkin-Elmer and Analytical Sciences, Boston, MA, USA). Results are expressed as counts per minute and presented as means±s.d. of triplicate experiments. As a proliferation control, 2Â10 5 splenocytes in 200 ml of complete medium were incubated for 3 days with phytohemagglutinin (SigmaAldrich) at a final concentration of 10 mg/ml.
Enzyme-linked immunosorbent assay for measuring mouse interferon-c
Interferon-g released by activated cells was measured in supernatants collected after day 5 by cytokine enzyme-linked immunosorbent assay (Mouse interferon-g, Bender MedSystem GmbH, Austria). The chromogenic substrate tetramethyl benzidine solution was added to the wells and the reaction stopped after 10 min with 1M phosphoric acid. Absorbance was measured at 450 nm as described above.
Analysis of EGFP DNA sequences by PCR
For conventional PCR analysis, EGFP sequences were identified using a PTC200 Peltier Thermal Cycler, MJ Research Inc. (Waltham, MA, USA). Genomic DNA was extracted using the DNAeasy Tissue Kit (QIAGEN, West Sussex, UK) according to the manufacturer's instructions. The primers for the EGFP sequence were EGFPF1: 5¢-AGCTCGATGCGGTTCACCAG-3¢and EGFPR1: 5¢-GCCACAAGTTCAGCGTGTCC-3¢. Amplification was performed using Taq DNA polymerase and the 100 mM dNTPs set (dAT, dCTP, dGTP and dTTP) (both by Invitrogen, Life Sciences, San Diego, CA, USA). The thermal profile was one hold of 2 min at 95 1C, 40 cycles at 94 1C 30 s, 57 1C 30 s and 72 1C 15 s and a final elongation at 72 1C 1 min. PCR products were analyzed by electrophoresis in 1% agarose gel. For quantitative PCR analysis, we used the TaqMan real-time PCR procedure. EGFP copy numbers were determined by the real-time quantitative PCR approach using a Rotor Gene RG-3000 (Corbett Research Products, Foxboro, MA, USA). Primers for the EGFP sequence were as follows: QEGFPF1: 5¢-GTAAACGGCCACAAGTTCAGC-3¢ and QEGFPR1: 5¢-TGGTGCAGATGAACTTCAGGG-3¢, and detected with the TaqMan probe MGBNFQ: FAM-5¢-CTTGCCGTAGGTGGC-3¢-BHQ1. Amplification of the murine genomic b-actin sequence was achieved using the primers: b-actin-MF: 5¢-ACGGCCAGGTCATCACTATTG-3¢ and b-actin-MR: 5¢-ACTATG GCCTCAAGG-AGTTTTGTCA-3¢, and detected with the TaqMan probe b-actin-T: 5¢-TR-AACGAGCGGTTCCGATGCCCT-BHQ2-3¢. The TaqMan Universal Mastermix, NoAmpErase UNG Applied Biosystems (ROCHE, Nutley, NJ, USA) was used for amplification. The cycling conditions were one hold of 10 min at 95 1C, followed by 55 cycles of 20 s at 95 1C and 30 s at 58 1C.
Statistical analysis
Groups were compared using the Wilcoxon Mann-Whitney U-test. All statistical tests were performed using Statgraphics Plus 5.0 software (Manugistics Inc., Rockville, MD, USA).
